HBV News and Research

RSS

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.

12 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).

16 Apr 2014

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014.

11 Apr 2014

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection.

10 Apr 2014

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Small financial incentives, totalling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination, according to new research published in The Lancet.

10 Apr 2014

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields.

2 Apr 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Scientists discover how viral DNA of HBV can be degraded in cell nucleus

Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing the virus to be eliminated.

24 Feb 2014

Monitoring individuals with chronic HBV is cost-effective strategy for China

A novel study determined that monitoring inactive chronic hepatitis B (HBV) carriers is a cost-effective strategy for China. However, results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that increasing treatment, monitoring and adherence to therapy are necessary to achieve significant health benefits at the population level.

16 Jan 2014

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Vaccination campaign led HBV to more than double rate of "breakout" mutations

A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

8 Oct 2013

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.

9 Sep 2013

Medivir discontinues development of hepatitis B compound MIV-210 on collaboration with Daewoong

Medivir AB today announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical Co. Ltd.,.

7 Sep 2013

Medivir, Daewoong Discontinue HBV Drug Development

...

6 Sep 2013

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

The hepatitis C virus hijacks the body's immune system, leaving T cells unable to function. A new study in animal models suggests that blocking a protein that helps the virus thrive could restore immune function, allowing the body to fight infection. The work, led by teams at The Research Institute at Nationwide Children's Hospital and Emory University, was published online Aug. 26 in the Proceedings of the National Academy of Sciences.

4 Sep 2013